Paul Hudson: Sanofi 'least exposed' to generic competition as Big Pharma doubles down on Dupixent
As Sanofi gears to change strategies to increase Dupixent sales and add indications amid a sprawling R&D trim, CEO Paul Hudson gave some insight into how it plans to move forward.
The plan is two-prong: Hudson told investors and analysts on the pharma’s Q2 earnings call that it’s the “least exposed” Big Pharma to the threat of generic competition through the rest of the 2020s, while its Regeneron-partnered Dupixent will become an even more important tool in Sanofi’s repertoire.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.